599 related articles for article (PubMed ID: 24107281)
1. Long-term antihypertensive effects of aliskiren, a direct renin inhibitor, in chronic hemodialysis patients.
Ishimitsu T; Ohta S; Ohno E; Takahashi T; Numabe A; Okamura A; Ohba S; Hashimoto A; Matsuoka H
Ther Apher Dial; 2013 Oct; 17(5):524-31. PubMed ID: 24107281
[TBL] [Abstract][Full Text] [Related]
2. Effects of aliskiren on blood pressure and the predictive biomarkers for cardiovascular disease in hemodialysis-dependent chronic kidney disease patients with hypertension.
Morishita Y; Hanawa S; Chinda J; Iimura O; Tsunematsu S; Kusano E
Hypertens Res; 2011 Mar; 34(3):308-13. PubMed ID: 21124333
[TBL] [Abstract][Full Text] [Related]
3. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
Horký K
Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
[TBL] [Abstract][Full Text] [Related]
4. Effects of aliskiren on blood pressure and humoral factors in hypertensive hemodialysis patients previously on angiotensin II receptor antagonists.
Ito T; Ishikawa E; Fujimoto N; Okubo S; Ito G; Ichikawa T; Nomura S; Ito M
Clin Exp Hypertens; 2014; 36(7):497-502. PubMed ID: 24433061
[TBL] [Abstract][Full Text] [Related]
5. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension.
Dietz R; Dechend R; Yu CM; Bheda M; Ford J; Prescott MF; Keefe DL
J Renin Angiotensin Aldosterone Syst; 2008 Sep; 9(3):163-75. PubMed ID: 18957387
[TBL] [Abstract][Full Text] [Related]
6. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension.
Andersen K; Weinberger MH; Constance CM; Ali MA; Jin J; Prescott MF; Keefe DL
J Renin Angiotensin Aldosterone Syst; 2009 Sep; 10(3):157-67. PubMed ID: 19617271
[TBL] [Abstract][Full Text] [Related]
7. Aliskiren reduces morning blood pressure in hypertensive patients with diabetic nephropathy on hemodialysis.
Takenaka T; Okayama M; Kojima E; Nodaira Y; Arai J; Uchida K; Kikuta T; Sueyoshi K; Hoshi H; Watanabe Y; Takane H; Suzuki H
Clin Exp Hypertens; 2013; 35(4):244-9. PubMed ID: 23534458
[TBL] [Abstract][Full Text] [Related]
8. A comparison of the antihypertensive and anti-inflammatory effects of aliskiren and ramipril add-on therapy in peritoneal dialysis patients--a pilot open label study.
Makówka A; Olejniczak-Fortak M; Nowicki M
Kidney Blood Press Res; 2012; 36(1):18-25. PubMed ID: 22777192
[TBL] [Abstract][Full Text] [Related]
9. [The future of renin inhibition].
Uresin AY; Baran E
Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
[TBL] [Abstract][Full Text] [Related]
10. A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension.
Strasser RH; Puig JG; Farsang C; Croket M; Li J; van Ingen H
J Hum Hypertens; 2007 Oct; 21(10):780-7. PubMed ID: 17541390
[TBL] [Abstract][Full Text] [Related]
11. Renin inhibition in hypertension.
Gradman AH; Kad R
J Am Coll Cardiol; 2008 Feb; 51(5):519-28. PubMed ID: 18237679
[TBL] [Abstract][Full Text] [Related]
12. Aliskiren, the future of renin-angiotensin system blockade?
Uresin Y; Mehtar Bozkurt M; Sabirli S; Ozunal ZG
Expert Rev Cardiovasc Ther; 2007 Sep; 5(5):835-49. PubMed ID: 17867914
[TBL] [Abstract][Full Text] [Related]
13. Aliskiren: an oral renin inhibitor for the treatment of hypertension.
Lam S; Choy M
Cardiol Rev; 2007; 15(6):316-23. PubMed ID: 18090068
[TBL] [Abstract][Full Text] [Related]
14. Aliskiren improves blood pressure control and prevents cardiac damage in high-risk hypertensive subjects.
Mazza A; Montemurro D; Zuin M; Schiavon L; Zorzan S; Chondrogiannis S; Ferretti A; Ramazzina E; Rubello D
Minerva Cardioangiol; 2013 Aug; 61(4):461-9. PubMed ID: 23846012
[TBL] [Abstract][Full Text] [Related]
15. Aliskiren: renin inhibitor for hypertension management.
Cheng JW
Clin Ther; 2008 Jan; 30(1):31-47. PubMed ID: 18343241
[TBL] [Abstract][Full Text] [Related]
16. Greater reductions in plasma aldosterone with aliskiren in hypertensive patients with higher soluble (Pro)renin receptor level.
Bokuda K; Morimoto S; Seki Y; Yatabe M; Watanabe D; Yatabe J; Ando T; Shimizu S; Itoh H; Ichihara A
Hypertens Res; 2018 Jun; 41(6):435-443. PubMed ID: 29618841
[TBL] [Abstract][Full Text] [Related]
17. Clinical role of direct renin inhibition in hypertension.
Taylor AA; Pool JL
Am J Ther; 2012 May; 19(3):204-10. PubMed ID: 21317620
[TBL] [Abstract][Full Text] [Related]
18. Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.
Dalla Vestra M; Simioni N; Masiero A
Minerva Endocrinol; 2009 Dec; 34(4):333-8. PubMed ID: 20046162
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension.
Uresin Y; Taylor AA; Kilo C; Tschöpe D; Santonastaso M; Ibram G; Fang H; Satlin A
J Renin Angiotensin Aldosterone Syst; 2007 Dec; 8(4):190-8. PubMed ID: 18205098
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety, tolerability, and antihypertensive efficacy of aliskiren, an oral direct renin inhibitor, in Japanese patients with hypertension.
Kushiro T; Itakura H; Abo Y; Gotou H; Terao S; Keefe DL
Hypertens Res; 2009 Mar; 32(3):169-75. PubMed ID: 19262478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
